Huluwa Pharmaceutical Group Named Among the 2024 Top 50 Most Competitive Companies in the Proprietary Chinese Medicine Industry

On August 10, 2024, the much-anticipated 2024 CPEO (China Health Ecology Organization) opened at the Boao Forum in Hainan Province. During the event, Huluwa Pharmaceutical Group was recognized as one of the 2024 Top 50 Most Competitive Companies in the Proprietary Chinese Medicine Industry, a powerful testament to its exceptional performance and outstanding innovations in the field. This recognition underscores Huluwa Pharmaceutical Group’s leadership and potent growth potential in the traditional Chinese medicine industry.

The conference brought together leading enterprises and industry experts from pharmaceutical and healthcare sectors at home and abroad to explore emerging trends, opportunities, and challenges shaping the healthcare industry. Among the many distinguished participants, Huluwa Pharmaceutical Group stood out for its comprehensive strengths and merits in research and development, innovation, marketing, promotion and brand building.

Committing itself to advancing children's health in China, Huluwa Pharmaceutical Group upholds its corporate mission of "Healthy Chinese Children". By fully integrating modern science and technology with the essence of traditional Chinese medicine, Huluwa Pharmaceutical executes rigorous research and development to preserve and enhance classical formulations, continuously delivering high-quality medicines. Over the years, it has grown into a leading enterprise in the pediatric healthcare sector in China.

In recent years, Huluwa Pharmaceutical Group has proactively fostered a green development ecosystem, focusing on the full life cycle of children's health. The Group has successfully developed a comprehensive portfolio of pediatric healthcare products and accelerated the development of an integrated industrial chain spanning innovative pediatric medicines, health foods, specialized medical nutrition, and medical devices. Currently, Huluwa Pharmaceutical offers more than 300 Chinese and Western medicines, covering therapeutic areas such as the respiratory and digestive systems, tonics, vitamins, and minerals. With the Huluwa pediatric brand at its core, the Group has established a diversified brand portfolio, including “HuluMom”, catering to women’s health, and “HuluShijia”, focusing on adult healthcare. Huluwa’s extensive marketing network spans over 2,300 counties and cities across more than 30 provinces and municipalities, fully leveraging medical institutions, OTC retail, three-terminal distribution, and emerging online retail channels.

Being named among the 2024 Top 50 Most Competitive Companies in the Proprietary Chinese Medicine Industry is both a recognition of Huluwa Pharmaceutical Group’s achievements and an effective catalyst for its future growth. The Group remains committed to innovation-driven development, continuously increasing investment in research and development, enhancing product quality and service levels, and striving to deliver safer and more effective treatments. Moving forward, Huluwa Pharmaceutical Group will continue its endeavors in advancing pediatric healthcare and contributing to the “Healthy China” initiative with greater dedication.